Companies › RemeGen
8 active drug programs in 252 registered trials: 172 Phase 2, 54 Phase 3, 22 Phase 1, 4 Phase 4; Oncology, Other, Genitourinary, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Disitamab Vedotin Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent | ERBB2, Tubulin | Phase 3 | Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer … | Dec 2026 |
| Toripalimab (JS001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Urothelial Carcinoma; Gastric Cancer; Breast Cancer; Biliary Tract Cancer (BTC) … | Dec 2026 |
| Telitacicept | – | Phase 3 | Primary IgA Nephropathy; Myasthenia Gravis, Ocular; ANCA Associated Vasculitis; ANCA-associated Vasculitis … | Dec 2026 |
| RC148 Monoclonal antibody targeting unknown oncology target | – | Phase 3 | Non-Small Cell Lung Cancer; Colorectal (Colon or Rectal) Cancer; Breast Cancer; Solid Tumor | May 2027 |
| RC108 MET-targeted therapy | – | Phase 2 | Non-Small Cell Lung Cancer | Dec 2027 |
| RC278 | – | Phase 1 | Solid Tumors | Dec 2027 |
| RC288 For Injection | – | Phase 1 | Solid Tumors | Dec 2029 |
| RC118-ADC Anti-CLDN18.2 antibody-drug conjugate with microtubule inhibitor payload | CLDN18 | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03930498 | Toripalimab (JS001) | Phase 2 | Recurrent Nasopharyngeal Carcinoma | Oncology | Nov 2023 |
| NCT05555888 | Toripalimab (JS001) | Phase 2 | Early Low Rectal Cancer | Oncology | Mar 2024 |
| NCT05586061 | Disitamab Vedotin | Phase 2 | HER2-positive Gastric Cancer | Oncology | Dec 2024 |
| NCT05586100 | Toripalimab (JS001) | Phase 2 | Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma | Oncology | Apr 2025 |
| NCT07098897 | Telitacicept | Phase 3 | IgA Nephropathy (IgAN) | Genitourinary | May 2025 |
| NCT05980481 | Disitamab Vedotin | Phase 2 | Gastric Cancer | Oncology | Jul 2025 |
| NCT05980481 | Toripalimab (JS001) | Phase 2 | Gastric Cancer | Oncology | Jul 2025 |
| NCT06020755 | Toripalimab (JS001) | Phase 2 | Gestational Trophoblastic Neoplasia | Other | Aug 2025 |
| NCT05205850 | RC118-ADC | Phase 1 | Advanced Solid Tumor | Oncology | Sep 2025 |
| NCT06020885 | Toripalimab (JS001) | Phase 1 | Esophageal Squamous Cell Carcinoma | Oncology | Oct 2025 |
| NCT07065435 | Disitamab Vedotin | Phase 2 | HER2 + Breast Cancer | Oncology | Dec 2025 |
| NCT05998759 | Telitacicept | Phase 2 | Connective Tissue Diseases | Hematology | Dec 2025 |
| NCT06293690 | Toripalimab (JS001) | Phase 2 | Non-small Lung Cancer | Oncology | Dec 2025 |
| NCT06016062 | RC148 | Phase 1 | Solid Tumor | Oncology | Dec 2025 |
| NCT05147844 | Toripalimab (JS001) | Phase 2 | Nasopharyngeal Carcinoma | Oncology | Dec 2025 |
| NCT05799287 | Telitacicept | Phase 3 | Primary IgA Nephropathy | Genitourinary | Jun 2026 |
| NCT06852287 | Toripalimab (JS001) | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Oncology | Sep 2026 |
| NCT07353723 | Toripalimab (JS001) | Phase 2 | Head & Neck Cancer | Oncology | Nov 2026 |
| NCT06462222 | Toripalimab (JS001) | Phase 1 | Leptomeningeal Metastasis | Oncology | Nov 2026 |
| NCT05943379 | Disitamab Vedotin | Phase 2 | NMIBC | Oncology | Dec 2026 |
| NCT06426511 | Toripalimab (JS001) | Phase 2 | Lung Cancer, Nonsmall Cell | Oncology | Dec 2026 |
| NCT06151743 | Toripalimab (JS001) | Phase 2 | Locally Advanced Hypopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT07446452 | Disitamab Vedotin | Phase 2 | HER2-low Breast Cancer | Oncology | Dec 2026 |
| NCT06178159 | Disitamab Vedotin | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06227117 | Disitamab Vedotin | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06221748 | Disitamab Vedotin | Phase 2 | Gastric Cancer | Oncology | Dec 2026 |
| NCT06178159 | Toripalimab (JS001) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06227117 | Toripalimab (JS001) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT03907826 | Toripalimab (JS001) | Phase 3 | Recurrent Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT05340491 | Toripalimab (JS001) | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT06323239 | Toripalimab (JS001) | Phase 2 | Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT06525428 | Toripalimab (JS001) | Phase 2 | Microsatellite Stable Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT06914440 | Toripalimab (JS001) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT04669496 | Toripalimab (JS001) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Dec 2026 |
| NCT06201065 | Toripalimab (JS001) | Phase 3 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT05912816 | Disitamab Vedotin | Phase 2 | Upper Urinary Tract Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT07093866 | Disitamab Vedotin | Phase 2 | mCRPC | Oncology | Dec 2026 |
| NCT06505837 | Toripalimab (JS001) | Phase 3 | Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06505837 | Toripalimab (JS001) | Phase 3 | Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06354231 | Toripalimab (JS001) | Phase 2 | Renal Insufficiency | Genitourinary | Dec 2026 |
| NCT05125055 | Toripalimab (JS001) | Phase 2 | Oral Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT05768464 | Toripalimab (JS001) | Phase 2 | Non-clear Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT05302284 | Disitamab Vedotin | Phase 3 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT06389006 | Disitamab Vedotin | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06730373 | Disitamab Vedotin | Phase 2 | HER2-positive Gastric Cancer | Oncology | Dec 2026 |
| NCT06992362 | Disitamab Vedotin | Phase 2 | Hepatoid Adenocarcinoma of Stomach | Oncology | Dec 2026 |
| NCT06572319 | Disitamab Vedotin | Phase 1 | HER2-positive Gastric Cancer | Oncology | Dec 2026 |
| NCT07249632 | Telitacicept | Phase 3 | Myasthenia Gravis, Ocular | Neurology | Dec 2026 |
| NCT05962840 | Telitacicept | Phase 4 | ANCA Associated Vasculitis | Immunology | Dec 2026 |
| NCT05965284 | Telitacicept | Phase 4 | ANCA-associated Vasculitis | Immunology | Dec 2026 |
| NCT05302284 | Toripalimab (JS001) | Phase 3 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT06389006 | Toripalimab (JS001) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT04523493 | Toripalimab (JS001) | Phase 3 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT05975307 | Toripalimab (JS001) | Phase 2 | Muscle-Invasive Bladder Carcinoma | Oncology | Dec 2026 |
| NCT05173246 | Toripalimab (JS001) | Phase 2 | Esophageal Small Cell Carcinoma | Oncology | Dec 2026 |
| NCT06187597 | Toripalimab (JS001) | Phase 2 | Locally Advanced Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT03859128 | Toripalimab (JS001) | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT04517214 | Toripalimab (JS001) | Phase 2 | Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT06690697 | Toripalimab (JS001) | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT05798845 | Toripalimab (JS001) | Phase 2 | NSCLC | Oncology | Dec 2026 |
The 60 nearest readouts of 252 trials; the rest in the app.
CSPC Megalith Biopharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Bio-Thera Solutions Dizal Pharmaceuticals BioRay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.